BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 23829302)

  • 1. Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.
    Lee CY; Cantle JP; Yang XW
    FEBS J; 2013 Sep; 280(18):4382-94. PubMed ID: 23829302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo.
    Graham RK; Deng Y; Carroll J; Vaid K; Cowan C; Pouladi MA; Metzler M; Bissada N; Wang L; Faull RL; Gray M; Yang XW; Raymond LA; Hayden MR
    J Neurosci; 2010 Nov; 30(45):15019-29. PubMed ID: 21068307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
    Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
    Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
    Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
    Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue-specific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum.
    Mende-Mueller LM; Toneff T; Hwang SR; Chesselet MF; Hook VY
    J Neurosci; 2001 Mar; 21(6):1830-7. PubMed ID: 11245667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.
    Kuhn A; Goldstein DR; Hodges A; Strand AD; Sengstag T; Kooperberg C; Becanovic K; Pouladi MA; Sathasivam K; Cha JH; Hannan AJ; Hayden MR; Leavitt BR; Dunnett SB; Ferrante RJ; Albin R; Shelbourne P; Delorenzi M; Augood SJ; Faull RL; Olson JM; Bates GP; Jones L; Luthi-Carter R
    Hum Mol Genet; 2007 Aug; 16(15):1845-61. PubMed ID: 17519223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
    Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
    Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment.
    Gafni J; Papanikolaou T; Degiacomo F; Holcomb J; Chen S; Menalled L; Kudwa A; Fitzpatrick J; Miller S; Ramboz S; Tuunanen PI; Lehtimäki KK; Yang XW; Park L; Kwak S; Howland D; Park H; Ellerby LM
    J Neurosci; 2012 May; 32(22):7454-65. PubMed ID: 22649225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
    Gray M; Shirasaki DI; Cepeda C; André VM; Wilburn B; Lu XH; Tao J; Yamazaki I; Li SH; Sun YE; Li XJ; Levine MS; Yang XW
    J Neurosci; 2008 Jun; 28(24):6182-95. PubMed ID: 18550760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.
    Oliveira JM
    J Neurochem; 2010 Jul; 114(1):1-12. PubMed ID: 20403078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
    Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
    J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.
    Tebbenkamp AT; Green C; Xu G; Denovan-Wright EM; Rising AC; Fromholt SE; Brown HH; Swing D; Mandel RJ; Tessarollo L; Borchelt DR
    Hum Mol Genet; 2011 Jul; 20(14):2770-82. PubMed ID: 21515588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
    Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
    Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.
    Gu X; Greiner ER; Mishra R; Kodali R; Osmand A; Finkbeiner S; Steffan JS; Thompson LM; Wetzel R; Yang XW
    Neuron; 2009 Dec; 64(6):828-40. PubMed ID: 20064390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
    Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy.
    Vidal RL; Figueroa A; Court FA; Thielen P; Molina C; Wirth C; Caballero B; Kiffin R; Segura-Aguilar J; Cuervo AM; Glimcher LH; Hetz C
    Hum Mol Genet; 2012 May; 21(10):2245-62. PubMed ID: 22337954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease.
    Valencia A; Reeves PB; Sapp E; Li X; Alexander J; Kegel KB; Chase K; Aronin N; DiFiglia M
    J Neurosci Res; 2010 Jan; 88(1):179-90. PubMed ID: 19642201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice.
    Gu X; Li C; Wei W; Lo V; Gong S; Li SH; Iwasato T; Itohara S; Li XJ; Mody I; Heintz N; Yang XW
    Neuron; 2005 May; 46(3):433-44. PubMed ID: 15882643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
    Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
    J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.